Meropenem
مروپنم
🦠 Antiinfectives For Systemic UseCarbapenem
Market / country: 🇺🇸 USA
Merrem (US)
🧮 Dose calculator
Skin and skin structure infection · Regimen source: FDA Meropenem · 2.1
- • 1 g every 8 h if Pseudomonas aeruginosa is suspected or confirmed. FDA Meropenem · 2.1
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to the drug or anaphylaxis with other beta-lactams. FDA Meropenem · 4
Warnings
- • Serious hypersensitivity; Clostridioides difficile-associated diarrhoea; seizures (especially with renal impairment). FDA Meropenem · 5
Important interactions
- • Valproic acid: marked fall in valproate levels and breakthrough seizures — not recommended together. FDA Meropenem · 5
Renal adjustment
- • eGFR < 50: CrCl 26–50: usual dose every 12 h; 10–25: half dose every 12 h; <10: half dose every 24 h. FDA Meropenem · 2.2
Formulations
- 500 mg vial — powder for injection 🇺🇸 USA FDA Meropenem · 3
- 1 g vial — powder for injection 🇺🇸 USA FDA Meropenem · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Meropenem · 8.1
“Risk Summary There are insufficient human data to establish whether there is a drug-associated risk of major birth defects or miscarriages with meropenem in pregnant women.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Meropenem · 8.2
“Risk Summary Meropenem has been reported to be excreted in human milk.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Meropenem · 8.4
“The safety and effectiveness of Meropenem for injection have been established for pediatric patients 3 months of age and older with complicated skin and skin structure infections and bacterial meningitis, and for pediatric patients of all ages with complicated intra-abdominal infections.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Meropenem · 8.5
“Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA210773
- DailyMed (FDA label)FDA Meropenem
- MedlinePlus (NIH)Meropenem Injection
- WHO ATC/DDDJ01DH02
- Darooyab (Iran)Meropenem
🇮🇷 Registered in Iran Darooyab · G-433/Meropenem
Dosage forms with Iranian generic codes, per Darooyab.
- 05629 · MEROPENEM 1G VIAL · ویال مروپنم ۱ گرم
- 03283 · MEROPENEM 500MG VIAL · ویال مروپنم ۵۰۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Meropenem · 3FDA Meropenem · 2.1FDA Meropenem · 2.3FDA Meropenem · 4FDA Meropenem · 5FDA Meropenem · 2.2FDA Meropenem · 8.1FDA Meropenem · 8.2FDA Meropenem · 8.4FDA Meropenem · 8.5FDA Meropenem · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-433/Meropenem
- Clinical review⚠ Unverified